Clinical Trial Detail

NCT ID NCT03112174
Title Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Pharmacyclics LLC.
Indications

mantle cell lymphoma

Therapies

Ibrutinib

Ibrutinib + Venetoclax

Age Groups: adult senior

No variant requirements are available.